ELV241220C420000
- 0.01
- 0.000.00%
Elevance Health Newsroom
Mizuho Securities Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $455
Elevance Health Price Target Lowered to $455 From $505 at Mizuho
Elevance Health (NYSE:ELV) Is Looking To Continue Growing Its Returns On Capital
Mizuho Adjusts Price Target on Elevance Health to $455 From $505, Keeps Outperform Rating
Elevance Health Stock Plunges 29.6% in Q4: Buy, Hold or Sell?
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
U.S. Healthcare Spending Climbs 7.5% in 2023
Your Healthcare Costs Are Soaring! US Spending Reached $5 Trillion In 2023 With Major Increase in Obesity and Diabetes Drugs, Hospital Services
25 U.S. 'Highest Conviction' Stocks – UBS
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
The Medical assistance program may come under pressure as Morgan Stanley downgrades Elevance Health (ELV.US).
Elevance Health (ELV.US) faces pressure in its Medical assistance Business, and Morgan Stanley downgraded the stock rating from "Shareholding" to "Hold" on Tuesday.
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Health-care Sector Faces Mixed Prospects in 2025, Morgan Stanley Says
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
UnitedHealth, CVS Health Extend Decline as Pfizer CEO Cites Trump's PBM Comments
Morgan Stanley Downgrades Elevance Health(ELV.US) to Hold Rating, Cuts Target Price to $388
Elevance Health Downgraded to Equal Weight From Overweight at Morgan Stanley
Morgan Stanley Sticks to Its Buy Rating for Elevance Health (ELV)